Navigation Links
University Participating in West Nile Vaccine Trial

Vanderbilt University Medical Center researchers, in collaboration with investigators at Johns Hopkins University, are beginning a Phase I trial to test// a new vaccine against the West Nile virus.

The mosquito-borne virus, which can cause serious illness, is making its yearly appearance in Middle Tennessee. While no human cases of West Nile have been reported in the state so far this season, mosquitoes collected from around Nashville have tested positive for the virus.

"When West Nile virus first appeared in the United States five or six years ago, it spread remarkably quickly across the country," said Peter Wright, M.D., professor of Pediatrics, Microbiology and Immunology, and Pathology, who is heading up Vanderbilt's efforts in the trial. "There's no part of the country that has not experienced human and bird cases of West Nile."

Although around 80 percent of people infected by West Nile virus show no symptoms, up to 20 percent can experience moderate or severe symptoms ranging from fever, headaches and neck stiffness to neurological problems, paralysis and coma. About one in 150 people infected develop severe illness. People over the age of 50 are at the highest risk, but even healthy people can experience debilitating symptoms lasting several weeks.

There are currently no specific treatments or vaccines to combat West Nile infection, so those infected are consigned to letting the illness run its natural course.

While it is not clear who would most benefit from a West Nile vaccine, Wright suggests that it could be beneficial to certain high-risk populations, such as the elderly, people who work outside and have frequent exposure to mosquitoes, or those in specific geographic regions where West Nile cases are detected.

Finding an effective vaccine against West Nile could also open doors to developing vaccines for other insect-borne illnesses like Dengue fever, which are a priority for vaccin e development because of their considerable global impact.

"We would love to get a vaccine developed for viruses in this class, called arthropod-borne, or as they are commonly called, arboviruses," Wright said. "If we could get one for West Nile, it could be a model for other vaccines."

The vaccine under investigation is built on a backbone of the Dengue virus with bits of the West Nile virus inserted. This method, called a chimeric vaccine, is a relatively new way to engineer a vaccine, Wright said.

"It's conceptually a very interesting vaccine," he said. "It's live but weakened, which has recently been postulated to be the ideal form of immunization…in terms of its broad stimulation of the immune response."

The researchers will test the safety of this vaccine as well as its ability to induce an immune response in healthy volunteers age 18 to 50. The study will also help identify an optimal dosage of the vaccine.

"We can learn a lot from it, and we can measure a lot of things that will inform us about how these vaccines work," Wright said.

Until an effective vaccine is found, public health officials urge the public to take steps to prevent mosquito bites. This includes using insect repellent when outdoors, limiting time spent outside around dawn and dusk when mosquitoes are most active, and getting rid of standing water where mosquitoes breed.

(Source: Newswise)
'"/>




Related medicine news :

1. Researchers at Cornell University as been reported using research fund by false claims
2. A new study by John Hopkins University proposes formula for good health
3. James Cook University urges more medical seats
4. Pill splitting program of University of Michigan can save money
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Yale University guidelines for Physicians and Pharmaceutical industry
7. $ 1.7 Million NYSTAR Award for Binghamton University to Flex Electronics Research Muscle.
8. Florida State University declares a breathtaking study which might solve the Hepatitis C Virus maze and find a cure!
9. Hwang Woo Suk Suspended By Seoul National University
10. Vladeck to head the University of Medicine and Dentistry of New Jersey
11. Rice University wins Prestigious Grants from HHMI
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/30/2016)... ... May 30, 2016 , ... Shaolin ... warrior 8-day-8 and 8-night special intensive summer training camp starts on June 17th ... camp offers families and children a fun and unique experience with an opportunity ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide ... we as a society can control and change. , As nearly 795,000 Americans suffering ... seconds within the United States. Plus, with an estimated 129,000 of these people dying ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
Breaking Medicine Technology: